55 Views | 31 Downloads
Valerie Relias, Tufts Medical Center, 800 Washington Street #245, Boston, MA 02111, USA. Email: vrelias1@tuftsmedicalcenter.org
Medical writing support was provided by Geraldine Thompson of Engage Scientific Solutions, and was funded by Pfizer.
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr Relias serves on Speakers Bureau for AbbVie and Genentech. Dr McBride is a consultant for Sandoz, Sanofi Genzyme, and Teva. Dr Newman has no potential disclosures to report. Dr Paul has no potential disclosures to report. Dr Saneeymehri has no potential disclosures to report. Ms Stanislaus discloses potential conflicts of interest with Celgene, Jazz, Novartis, and Takeda. Dr Tobin is a consultant for KaryoPharm. Drs Hoang and Ryan are employees of Pfizer. Ms Galinsky is a consultant/advisory board member for AbbVie, Merus Pharmaceuticals, and Pfizer.
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The BRIGHT AML 1003 trial reviewed in this article is a clinical study sponsored by Pfizer. Pfizer funded a meeting for discussion of glasdegib, and provided a formal review of the publication, including for medical accuracy, but the authors had final authority, including choice of journal. The authors were compensated for expenses for their attendance at the meeting, but were not compensated for manuscript preparation.
© The Author(s) 2020